The UK’s National Health Service has approved mirvetuximab soravtansine, a groundbreaking targeted therapy that represents the first new treatment option for ovarian cancer in over 20 years. This antibody-drug conjugate offers critical hope for hundreds of women whose platinum-resistant disease has stopped responding to conventional chemotherapy approaches.
The drug works by precisely targeting folate receptor alpha, a protein present in approximately 80% of ovarian cancer cases. By binding directly to cancer cells and delivering a cytotoxic payload, mirvetuximab soravtansine maximizes anti-tumor effects while minimizing damage to healthy tissue—a significant advantage over traditional chemotherapy. NHS England’s approval addresses a substantial clinical need, as platinum-resistant ovarian cancer remains one of the most challenging forms to treat effectively.
This approval follows comprehensive clinical trial data and represents a watershed moment for ovarian cancer patients who have exhausted standard treatment options. Read the full article on GMJ Newsroom.
Was this article helpful?
